全文获取类型
收费全文 | 179110篇 |
免费 | 4009篇 |
国内免费 | 2114篇 |
专业分类
耳鼻咽喉 | 1682篇 |
儿科学 | 6400篇 |
妇产科学 | 2731篇 |
基础医学 | 21609篇 |
口腔科学 | 4437篇 |
临床医学 | 12471篇 |
内科学 | 35026篇 |
皮肤病学 | 3045篇 |
神经病学 | 10988篇 |
特种医学 | 3620篇 |
外国民族医学 | 4篇 |
外科学 | 26604篇 |
综合类 | 11907篇 |
现状与发展 | 2篇 |
一般理论 | 4篇 |
预防医学 | 8916篇 |
眼科学 | 3305篇 |
药学 | 21007篇 |
11篇 | |
中国医学 | 6450篇 |
肿瘤学 | 5014篇 |
出版年
2022年 | 1036篇 |
2021年 | 2561篇 |
2020年 | 1348篇 |
2019年 | 12917篇 |
2018年 | 12541篇 |
2017年 | 5773篇 |
2016年 | 1367篇 |
2015年 | 1494篇 |
2014年 | 3379篇 |
2013年 | 5307篇 |
2012年 | 3500篇 |
2011年 | 3638篇 |
2010年 | 3093篇 |
2009年 | 3042篇 |
2008年 | 3502篇 |
2007年 | 4569篇 |
2006年 | 4772篇 |
2005年 | 4653篇 |
2004年 | 3641篇 |
2003年 | 3696篇 |
2002年 | 3483篇 |
2001年 | 3460篇 |
2000年 | 3655篇 |
1999年 | 3289篇 |
1998年 | 3328篇 |
1997年 | 2706篇 |
1996年 | 2522篇 |
1995年 | 2835篇 |
1994年 | 2662篇 |
1993年 | 2112篇 |
1992年 | 1696篇 |
1991年 | 1668篇 |
1990年 | 1417篇 |
1989年 | 1131篇 |
1988年 | 1150篇 |
1987年 | 1095篇 |
1986年 | 932篇 |
1985年 | 5520篇 |
1984年 | 7348篇 |
1983年 | 5897篇 |
1982年 | 6319篇 |
1981年 | 5767篇 |
1980年 | 4948篇 |
1979年 | 5002篇 |
1978年 | 4084篇 |
1977年 | 3056篇 |
1976年 | 3526篇 |
1975年 | 2735篇 |
1974年 | 2526篇 |
1973年 | 2227篇 |
排序方式: 共有10000条查询结果,搜索用时 250 毫秒
41.
42.
43.
Khaled Adil Marija Popovic Fabio L. Cury Sergio L. Faria Marie Duclos Luis Souhami 《Practical radiation oncology》2019,9(1):24-28
Purpose
This study aimed to investigate 3 planning target volume (PTV) margin expansions and determine the most appropriate volume to be used in bladder preservation therapy when using daily cone beam computed tomography (CBCT). We aimed to establish whether a smaller PTV expansion is feasible without risking geographical miss.Methods and materials
The study included patients with bladder cancer who were treated with a hypofractionated course of radiation therapy delivered with intensity modulated radiation therapy. The clinical target volume (CTV) was the whole empty bladder, and the PTV consisted of a 1.5-cm margin around the bladder (PTV1.5 cm). Patients underwent daily CBCT imaging before treatment to assess the bladder volume and ensure accurate positioning. We investigated 2 additional smaller PTV margin expansions to determine the most appropriate volume to be used with CBCT as a daily image guided radiation therapy modality. These margins were created retrospectively on every CBCT. The first additional volume was a uniform PTV margin of the surrounding 1 cm (PTV1 cm). When considering that the majority of the internal bladder movement was due to the variation in filling that occurs in the superior and anterior directions, a second volume of an anisotropic PTV margin with a 1.5-cm superior/anterior and 1 cm in other directions (PTV1/1.5 cm) was created. We recorded the frequency and measured the volume of bladder falling out of each PTV based on the daily CBCT.Results
For the purpose of this study, we considered an arbitrary 5 cm3 of CTV falling out of the designated PTV as a clinically significant volumetric miss. The frequency of such a miss when applying the uniform PTV1 cm was 1%. However, when applying the uniform PTV1.5 cm and anisotropic PTV1/1.5 cm margins, the frequency was 0.5% and 0.5%, respectively.Conclusions
The anisotropic PTV expansion of 1.5 cm superiorly and anteriorly and 1 cm in all other directions around the bladder (CTV) provides a safe PTV approach when daily CBCT imaging is used to localize an empty bladder. 相似文献44.
45.
46.
Ngai-Yin Chan Chi-Chung Choy Ho-Chuen Yuen Hoi-Fan Chow Ho-Fai Fong 《The Canadian journal of cardiology》2019,35(4):396-404
Background
Persistent iatrogenic atrial septal defect (iASD) is a common but poorly characterized complication after cryoballoon (CB) pulmonary vein isolation (PVI) procedures. We therefore investigate its prevalence, evolution, risk factors, and clinical outcomes in a prospective longitudinal study.Methods
A total of 108 patients (41 women, mean age 57 ± 11.3) underwent CB PVI for AF. Serial transesophageal echocardiography (TEE) was performed 9 months and then annually until 6 years after the procedure to study the characteristics of persistent iASD.Results
Persistent iASD occurred in 33 (30.6%) patients 9 months after CB PVI. Spontaneous closure of iASD was found in 6 (22.2%) and 3 (15.8%) patients 2 and 3 years after the procedures, respectively. No spontaneous closure was observed on 4, 5, and 6-year TEE follow-up. The projected long-term persistence rate of iASD after CB PVI was therefore 20% (30.6% × 0.778 × 0.842). Using multivariate logistic regression, a higher number of cryoapplications (≥ 2 minutes) was the only independent predictor of persistent iASD 9 months after CB PVI (odds ratio [OR] 1.207; 95% confidence interval [CI], 1.033-1.411, P = 0.018). Two (1.9%) patients with significantly larger iASD size than the others (long diameter 12.6 ± 0.8 vs 3.7 ± 1.5 mm, P < 0.001; short diameter 10.9 ± 0.2 vs 3 ± 1.1 mm, P < 0.001) required percutaneous closure because of exertional dyspnea and right ventricular enlargement. Over 129.7 patient-years follow-up, during which iASD persisted, there was no occurrence of neurologic events.Conclusions
Approximately one fifth of patients undergoing CB PVI will have permanently persistent iASD. Patients with defect sizes of greater than 10 mm may need percutaneous closure due to significant left-to-right shunting. 相似文献47.
48.
49.
Joobin Sattar Adi Kartolo Wilma M. Hopman Joshua Matthew Lakoff Tara Baetz 《Journal of Geriatric Oncology》2019,10(3):411-414
ImportanceImmunotherapy has emerged as an effective treatment option for the management of advanced cancers. The effects of these immune checkpoint inhibitors in the older patient population has not been adequately assessed.ObjectiveTo understand the impact of aging on CTLA-4 and PDL-1 inhibitors efficacy and immune-related adverse events (irAE) in the context of real-world management of advanced solid cancers.Design, Setting, and ParticipantsThis retrospective study involved all non-study patients with histologically-confirmed metastatic or inoperable solid cancers receiving immunotherapy at Kingston Health Sciences Centre. We defined ‘older patient’ as age ≥ 75. All statistical analyses were conducted under SPSS IBM for Windows version 24.0.Main Outcomes and MeasuresStudy outcomes included immunotherapy treatment response, survival, as well as number, type, and severity of irAEs.ResultsOur study (N = 78) had 29 (37%) patients age <65, 26 (33%) patients age 65–74, and 23 (30%) patients age ≥75. Melanoma, non-small cell lung cancer, and renal cell carcinoma accounted for 70%, 22%, and 8% of the study population, respectively. Distributions of ipilimumab (32%), nivolumab (33%), and pembrolizumab (35%) were similar in the study. The response rates were 28%, 27%, and 39% in the age <65, age 64–74, age ≥75 groups, respectively (P = 0.585). Kaplan-Meier curve showed a median survival of 28 months (12.28–43.9, 95% CI) and 17 months (0–36.9, 95% CI) in the age <65 and age 64–74 groups, respectively; the estimated survival probability did not reach 50% in the age ≥75 group (P = 0.319). There were no statistically significant differences found in terms of irAEs, multiple irAEs, severity of grade 3 or higher, types of irAEs, and irAEs resolution status when comparing between different age groups.Conclusion and RelevanceOur results suggest that patients age ≥75 are able to gain as much benefit from immunotherapy as younger patients, without excess toxicity. Our findings suggest that single agent immunotherapy is generally well-tolerated across different age groups with no significant difference in the type, frequency or severity of irAEs. Future studies evaluating aging and combination immunotherapy are warranted. 相似文献
50.